AbbVie Wins FDA Approval for Juvmo Treatment for Parkinson's Disease
AbbVie received FDA approval for Juvmo (tavapadon), a new once-daily treatment for Parkinson's disease, expected in October. Additionally, the company announced an AI-driven collaboration with Iambic
Kalkine Media · 2026-09-29 16:54 UTC